Oramed Pharmaceuticalsの空売り状況は、投資家がOramed Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Oramed Pharmaceuticals (NASDAQ:ORMP) 株価情報, 空売り情報

Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals Inc

Oramed Pharm (ORMP) just unveiled an update. Oramed Pharmaceuticals Inc. has announced the appointment of Mr. Avraham Gabay as the new Chief Financ...

Oramed Pharm Names Avraham Gabay as New CFO

Oramed Pharmaceuticals authorizes share buyback program

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>When discussing micro-cap stocks, it&rsquo;s important to recognize their general overlap with the world of <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks.</a> These stocks trade as shares of companies with market capitalizations between $50 million and $300 million. While those numbers may sound worthy to the individual investor, they represent a generally risky position for a handful of reasons.</p>



<p>The first is that micro-cap stocks are often derived from young and relatively unproven companies. Just because a company publicly trades on the <strong>Nasdaq </strong>does not make it a safe investment. The second is that these micro-cap stocks tend to experience less frequent trading than more major companies. This low liquidity can make it harder to sell out of a position should it no longer be lucrative.</p>



<p>Bearing these risks in mind, savvy investors know the value of getting in early on a profitable company. That&rsquo;s because all investing is a function of growth multiplied by time &mdash; the more time, the more potential for growth for your portfolio. Thus, here are three solid micro-cap stocks to consider if you&rsquo;re comfortable with the risk.</p>



<h2>Amplify Energy (AMPY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/oilandgasstocks1600-300x169.png" alt="Panorama of Oil and Gas central processing platform in twilight, offshore hard work occupation twenty four working hours. Best oil stocks to buy. Oil &amp; Gas Stocks to Avoid"><div>Source: Oil and Gas Photographer / Shutterstock.com</div></div><p>Small oil and natural gas companies might not be the first thing to come to mind when considering micro-cap stocks, but <strong>Amplify Energy </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ampy-stock-quote/"><strong>AMPY</strong></a></span>) is worth putting on your radar. The company is an independent developer focused on acquiring and exploiting oil and natural gas properties exclusively within the United States.</p>



<p>Geographically, the company focuses on <a href="https://www.amplifyenergy.com/operations/default.aspx">low-cost regions</a> for development like Oklahoma, East Texas and North Louisiana, with more expensive basins like the federal waters off the coast of Southern California and the Rocky Mountain West. Year-to-date, the company is up over 12% in value as part of its generally promising financial performance.</p>



<p>Though the company experienced a loss of <a href="https://www.google.com/finance/quote/AMPY:NYSE?sa=X&amp;ved=2ahUKEwj5o5D_tpeHAxVphP0HHWu5BnwQ3ecFegQINxAf">$9.4 million</a> for the first quarter of 2024, it succeeded in surpassing earnings-per-share forecasts by 0.85%, lending hope that its expansion expenses would not hamper its long-term growth. Thus, investors might want to get in early on this geographically diverse and well-managed company.</p>



<h2>Spero Therapeutics (SPRO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/doctor_medicine_dna_1600-300x169.jpg" alt="Various graphical representations of medical imagery are shown in front of a doctor using a tablet computer. DNA stock"><div>Source: Shutterstock / PopTika</div></div><p>Perhaps one of the biggest challenges facing modern medicine today is drug-resistant bacteria. This is especially true when considering that just in the U.S. alone more than 2.8 million antimicrobial-resistant infections occur annually, resulting in <a href="https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html">35,000 deaths.</a> To address this problem and take advantage of a new sector of antibiotic treatments, <strong>Spero Therapeutics </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/spro-stock-quote/"><strong>SPRO</strong></a></span>) has gone all-in on developing medicines for multidrug-resistant infections.</p>



<p>Currently, the company is developing several drugs at varying points in the development pipeline, but its most promising candidate seems to be <a href="https://www.sperotherapeutics.com/patients/spr-206">SPR206</a> under the brand name. This drug has reached Phase 2 clinical trials and has shown effectiveness against bacterial pneumonia acquired from hospital ventilator treatments.</p>



<p>While SPRO certainly isn&rsquo;t the only company focused on developing treatments for multidrug-resistant bacteria, its status among micro-cap stocks gives it significant potential to spike following a Food and Drug Administration regulatory approval.</p>



<h2>Oramed Pharmaceuticals (ORMP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div><p>Another fledgling biotech company, <strong>Oramed Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ormp-stock-quote/"><strong>ORMP</strong></a></span>) aims to address drug accessibility with its product pipeline. One of the factors that can significantly complicate or increase the cost of a treatment is its delivery route. As such, treatments that require injections to successfully enter the body tend to be more expensive due to the cost of syringes, professional injection services and the overall supply chain involved with jabs.</p>



<p>Oramed aims to do away with this, particularly in the <a href="https://oramed.com/pipeline/">insulin delivery sector,</a> by developing oral capsules that bypass stomach absorption and enter the intestine for direct uptake into the bloodstream. In the case of insulin, this would make treating diabetes as simple as taking a pill rather than relying on expensive pumps or complicated needles.</p>



<p>This route of treatment would also expand insulin coverage to developing countries where infrastructure does not allow for easy storage and accessibility to syringes while also nullifying <a href="https://wchh.onlinelibrary.wiley.com/doi/full/10.1002/pdi.2090">infection risks</a> as a result of unsanitary injection practices.</p>



<p><em>On the date of publication, Viktor Zarev did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com </em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines.</em></a></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/3-micro-cap-moonshots-for-fearless-investors/">3 Micro-Cap Moonshots for Fearless Investors</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Micro-Cap Moonshots for Fearless Investors

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Oramed Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ormp-stock-quote/"><strong>ORMP</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Oramed Pharmaceuticals reported earnings per share of 22 cents. This was above the analyst estimate for EPS of 1 cent.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/ormp-stock-earnings-oramed-pharmaceuticals-for-q2-of-2024/">ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q2 2024

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Oramed Pharm (ORMP – Research Report) today. The company's shares closed last Fri...

Oramed Pharm (ORMP) Receives a Hold from H.C. Wainwright

The latest announcement is out from Oramed Pharm ( ($ORMP) ). Oramed Pharmaceuticals Inc. has restructured its financial relationship with Scilex H...

Oramed Pharmaceuticals Reinforces Scilex Financial Ties

Scilex (SCLX) Holding Company has voluntarily made an early installment payment in the aggregate amount of $13.2 million under its senior secured p...

Scilex announces early installment payment on senior secured promissory note

Oramed (ORMP) has entered into definitive agreements to spin off its Protein Oral Delivery – POD – technology into a newly formed joint venture, Or...

Oramed enters JV for insulin development and commercialization

Oramed announces spinoff of protein drug technology

The latest update is out from Oramed Pharm ( ($ORMP) ). On February 7, 2025, Oramed Pharmaceuticals entered into a Supplemental Agreement to amend ...

Oramed Pharm Amends Joint Venture for OraTech Launch

AMPY

ORMP

SCLX

SPRO

Small Cap

Press Releases

Oramed Letter to Shareholders

Health Care

Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

Comments

Oramed Pharmaceuticals

空売り

Oramed Pharmaceuticals (NASDAQ:ORMP) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル